Navigation Links
Accumetrics, Inc. Announces 1000th Patient Enrolled in GRAVITAS Trial
Date:5/13/2009

SAN DIEGO, May 13 /PRNewswire/ -- Accumetrics, Inc. announces that it has enrolled its 1,000th patient into its landmark clinical trial, GRAVITAS (Gauging Responsiveness with A VerifyNow(R) Assay Impact on Thrombosis And Safety). The trial is specifically designed to demonstrate the value of providing clinicians with actionable information for patients who are poor responders to clopidogrel (Plavix(R)). The multi-center, placebo controlled trial will determine whether tailored antiplatelet therapy for poor responders, identified based on the results of the company's VerifyNow P2Y12 Test, reduces major cardiovascular adverse events (e.g., heart attack, stent thrombosis) following percutaneous coronary intervention (PCI). Currently the trial is being conducted at more than 70 sites in the U.S. and Canada, with a total enrollment goal of approximately 2,800 patients.

"This is a very significant milestone for Accumetrics as it brings us ever-closer to our goal of demonstrating the value of the VerifyNow System. By identifying and adjusting therapy for patients that are not responding adequately to standard doses of clopidogrel, GRAVITAS will be the largest multi-center clinical trial that links testing with personalized medicine and improved outcomes. We believe that the VerifyNow System will be seen as an integral tool in ensuring that patients receive not only the most appropriate antiplatelet therapy, but also the adequate dose," said Jeff Dahlen, Ph.D, Vice President, Clinical and Regulatory Affairs of Accumetrics, Inc. "We are very proud to reach this milestone, and look forward to completing enrollment soon, and sharing the results."

About GRAVITAS

The concept of variability in response to antiplatelet therapy has been well established. The question of whether poor response to antiplatelet therapy, as measured by a laboratory test, leads to poor outcomes is also being demonstrated with increased frequency. However, Accumetrics recognizes the need for a study specifically designed to demonstrate the value of providing clinicians with actionable information to improve outcomes for those patients who are poor responders to antiplatelet therapy. As a result, the GRAVITAS study is the first multi-center, placebo-controlled study to determine whether tailored antiplatelet therapy based on the results of the company's VerifyNow System reduces major cardiovascular adverse events post-PCI.

About Accumetrics (www.accumetrics.com)

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy to use platform for measuring an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, Plavix, ReoPro(R), and Integrilin(R), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc., Plavix is a registered trademark of Sanofi-Aventis, ReoPro is a registered trademark of Centocor, Inc., and Integrilin is a registered trademark of Millennium Pharmaceuticals.

    CONTACT:
    Jules Abraham
    Lippert/Heilshorn & Associates
    212-838-3777
    jabraham@lhai.com

    Timothy I. Still
    President and CEO
    Accumetrics
    858-404-8260
    press@accumetrics.com


'/>"/>
SOURCE Accumetrics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Accumetrics, Inc. Announces United Kingdom Distribution Agreement With ELITech UK Limited
2. Gregory J. Tibbitts Appointed Chief Financial Officer at Accumetrics, Inc.
3. Ad de Waard Appointed Vice President of International Sales and Marketing at Accumetrics, Inc.
4. Accumetrics, Inc. Appoints William Dippel as Executive Vice President of Operations and R&D
5. St. Lukes Episcopal Hospital Announces Latest Phase of Efficiency, Excellence and Engagement Campaign
6. Cyberonics Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2009 Financial Results
7. HealthWorldNet.com Announces HealthWiNs Awards
8. China Medicine Announces First Quarter 2009 Results
9. Misonix Announces Participation in Annual Diabetic Foot Global Conference
10. Pregis Announces First Quarter 2009 Financial Results
11. BioMed Realty Trust Announces Public Offering of 14,000,000 Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... CO (PRWEB) , ... March 23, 2017 , ... ... serving the families and businesses of the greater Fort Collins area, has unveiled ... in their ongoing community involvement program. Donations to this worthy cause may now ...
(Date:3/23/2017)... , ... March 23, 2017 , ... After raising more ... FaceCradle , the most-funded travel pillow in crowdfunding history, has established a ... its wildly popular travel innovation to Americans. , “We’re excited to be operating on ...
(Date:3/23/2017)... ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and Health System Executive ... Healthcare: Susan Salka , 43rd President of the United States of America: George ... Life In and Out of the Ring: Sugar Ray Leonard , JD, Chairperson, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Sharon Kleyne, host of the nationally syndicated ... Health on VoiceAmerica, recently talked on her program about how she is looking forward ... remind listeners of an important distinction. World Water Day, Kleyne pointed out, is an ...
(Date:3/23/2017)... ... 23, 2017 , ... Natural Subsistence, a company known for ... and nutrition, announced its product Leyzene is now available for purchase on Go4ItNutrition.com, ... that help people improve all aspects of their health so they can live ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... SAN DIEGO , March 23, 2017 /PRNewswire/ ... for fast and accurate identification of individuals who ... at risk for a rare yet potentially deadly ... seizures and bipolar disorder.  The gene HLA-B*15:02 ... hypersensitivity reactions such as Stevens-Johnson syndrome and toxic ...
(Date:3/23/2017)... March 23, 2017 On ... the trading session at 5,821.64, up 0.48%; the ... finish at 20,661.30; and the S&P 500 closed ... based as six out of nine sectors ended ... initiated reports coverage on the following Medical Instruments ...
(Date:3/23/2017)... , March 23, 2017 Pre-market ... MYL), Allergan PLC (NYSE: AGN), Horizon Pharma PLC (NASDAQ: HZNP), ... Generic Drugs stocks are part of the Healthcare sector, which ... nd , 2017, with the NYSE Health Care Index adding ... in the S&P 500 also were up nearly 0.1% as ...
Breaking Medicine Technology: